9/23
08:46 am
cccc
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
9/23
08:43 am
cccc
Rating for CCCC
Medium
Report
Rating for CCCC
9/23
08:43 am
cccc
Rating for CCCC
Medium
Report
Rating for CCCC
9/23
06:47 am
cccc
Rating for CCCC
Medium
Report
Rating for CCCC
9/23
06:47 am
cccc
Rating for CCCC
Medium
Report
Rating for CCCC
9/22
08:40 am
cccc
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Stephens. They now have a $6.00 price target on the stock.
High
Report
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Stephens. They now have a $6.00 price target on the stock.
9/22
08:40 am
cccc
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Stephens. They now have a $6.00 price target on the stock.
High
Report
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Stephens. They now have a $6.00 price target on the stock.
9/22
08:21 am
cccc
Rating for CCCC
High
Report
Rating for CCCC
9/22
08:05 am
cccc
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
High
Report
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
9/18
06:43 am
cccc
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.